FDA’s first AI-focused cGMP warning letter signals new scrutiny for manufacturers - BioSpace

The FDA has issued its first warning letter specifically focused on AI use in manufacturing, signaling stricter oversight of medical device makers. This affects how companies must validate and document AI in healthcare products.